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Background: Enumeration of circulating tumor cells (CTCs) obtained from minimally invasive blood samples has
been well established as a valuable monitoring tool in metastatic and early breast cancer, as well as in several other
cancer types. The gold standard technology for detecting CTCs in blood against a backdrop of millions of leukocytes is
the FDA-approved CellSearch system (Janssen Diagnostics), which relies on EpCAM-based immunomagnetic separation.
Secondary characterization of these cells could enable treatment selection based on specific targets in these cells, as
well as providing a real time window into the metastatic process and offering unique insights into tumor heterogeneity.
The objective of this study was to develop a method for downstream characterization of CTCs following isolation with
the CellSearch system.
Methods: An in vitro CTC model system focusing on clinically useful treatment predictive biomarkers in breast cancer,
specifically the estrogen receptor α (ERα) and the human epidermal growth factor receptor 2 (HER2), was established
using healthy donor blood spiked with breast cancer cell lines MCF7 (ERα+/HER2−) and SKBr3 (ERα−/HER2+). Following
CTC isolation by CellSearch, the captured CTCs were further enriched and fixed on a microscope slide using the
in-house-developed CTC-DropMount technique.
Results: The recovery rate of CTCs after CellSearch Profile analysis and CTC-DropMount was 87%. A selective and
consistent triple-immunostaining protocol was optimized. Cells positive for DAPI, cytokeratin (CK) 8, 18 and 19, but
negative for the leukocyte-specific marker CD45, were classified as CTCs and subsequently analyzed for ERα and HER2
expression. The method was verified in breast cancer patient samples, thus demonstrating its clinical relevance.
Conclusions: Our results show that it is possible to ascertain the status of important predictive biomarkers expressed in
breast cancer CTCs using the newly developed CTC-DropMount technique. Downstream characterization of multiple
biomarkers using a standard fluorescence microscope demonstrates that important clinical and biological information
may be obtained from a single patient blood sample following either CellSearch epithelial or profile analyses.
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During the last decade, enumeration of circulating
tumor cells (CTCs) in peripheral blood was established
as a prognostic tool for predicting time-to-recurrence
and survival in metastatic and early breast cancer, as well
as in several other cancer types [1-4]. The gold standard
technology, and the only platform implemented on a lar-
ger scale, is the FDA-approved semi-automated CellSearch
technology (Jansen Diagnostics, Raritan, NJ, USA). In
CellSearch, enriched EpCAM-positive CTCs are defined
as nucleated cells positive for cytokeratin (CK) 8, 18 and
19, but negative for the leukocyte-specific surface protein,
CD45. However, the field of CTC research is now moving
beyond solely quantifying cells in peripheral blood. Pheno-
typic and molecular characterization of CTCs has the po-
tential to provide clinically important information from an
easily accessible blood sample, a ‘liquid biopsy’. Serial
blood sampling followed by molecular characterization
can provide insights into tumor progression and enable
early detection of treatment resistance.
In breast cancer, assessment of estrogen receptor α
(ERα) status in the primary tumor is crucial in classifica-
tion and treatment prediction [5]. Determining receptor
status identifies patients eligible for endocrine therapy,
which remains the mainstay adjuvant treatment for
ERα+ breast cancers, either as monotherapy or in con-
junction with chemotherapy. Although an ERα+ primary
tumor is a common trait and found in approximately
80% of patients with primary breast cancer, it is no guar-
antee for a favorable outcome following endocrine treat-
ment as recurrence rates of 19–41% are observed at
10 years following 5 years of tamoxifen [6-8]. Moreover,
in metastatic breast cancer, approximately 40–50% of
patients fail to respond to endocrine treatment, despite
an initially positive assay [9]. The causes of this consid-
erable inconsistency are multifactorial and have not been
entirely elucidated, but discordance in ERα status be-
tween the primary tumor and involved lymph nodes or
distant metastases has been established in 6–30% of
studied cases and may contribute to treatment resistance
[10-14]. In fact, this phenotypical shift is associated with
significantly shorter median survival for patients with
metastatic disease when compared with consistent ERα-
positivity in disease progression [10]. Additionally, it has
been reported that the majority of CTCs in patients with
ERα+ primary tumors are in fact ERα− prior to therapy,
with a concordance of less than 30% [15-17].
Human epidermal growth factor receptor 2 (HER2) is a
tyrosine kinase receptor encoded by a proto-oncogene lo-
cated on chromosome 17 (17q12), and is the second most
important predictive biomarker in breast cancer [18,19].
Amplification of this gene occurs in approximately 10–30%
of primary breast cancers, correlating with poor prognosis
and an aggressive phenotype [18,19]. This subgroup ofpatients benefits from immunotherapy with an HER2-
targeted monoclonal antibody, trastuzumab, in combin-
ation with chemotherapy in adjuvant, neoadjuvant and
metastatic settings [20,21]. Similar to the dynamic pro-
gression observed in ERα+ tumors, the HER2 status of me-
tastases can differ from that of the primary tumor [22].
Discordance has been observed in 7–14% of studied cases
[11,23-25]. It has been shown that patients with HER2−
tumors might acquire HER2 amplification during disease
progression, as demonstrated by isolation of HER2+ CTCs
in patients with an HER2− primary tumor [26-29]. An-
other explanation for the discrepancy in biomarker ex-
pression between primary tumors and CTCs may be
tumor heterogeneity. Tumor clones shed into the blood
stream are more likely to represent those with most malig-
nancy, exemplified by HER2-amplified clones, despite the
primary tumor being diagnosed as HER2 normal. These
patients are less likely to receive HER2-targeted treatment,
although a complete or partial response has been observed
in selected cases [30]. Two prospective trials including pa-
tients with HER2-negative primary tumors and HER2-
positive CTCs are currently open for recruitment and aim
to elucidate whether trastuzumab will have a beneficial
effect on these cases [31].
Thus, treatment decisions based on the phenotype of
the primary tumor alone might omit critical facts rele-
vant to the prognosis and choice of treatment. Biopsies
from metastatic sites are not always available for prac-
tical reasons and are inevitably accompanied by an inva-
sive procedure. CTCs are easily accessible from a
normal blood sample, and since CTCs are shed from
multiple metastatic sites as well as from the primary
tumor, characterization of these cells could provide im-
portant information for treatment prediction.
The aim of this study was to establish a method for
downstream characterization of multiple treatment pre-
dictive markers expressed by CTCs after CellSearch-based
selection, without the necessity of additional patient sam-
ples. Validation of the method in samples from patients
with metastatic breast cancer highlights the potential of
the clinical utility of this technique.
Methods
In vitro model
Breast cancer cell lines MCF7 and SKBr3 were obtained
from the American Type Culture Collection (ATCC/LGC
Standards GmbH, Wesel, Germany) and were used to es-
tablish an in vitro model system for CTC characterization
following CellSearch isolation. MCF7 expresses ERα but is
negative for HER2 amplification. Contrary, SKBr3 cells are
HER2-positive and negative for ERα. MCF7 cells were
grown in a 5.0% CO2 incubator under UV-light at
37°C in culture vessels containing 5 mL MEM/EBSS
(HyClone Laboratories, Inc., Utah, United States) medium
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amino acids, 10% fetal bovine serum (FBS) and 1% penicil-
lin streptomycin mixture (Pen-Strep) for MCF7, and
RPMI 1640 (HyClone Laboratories, Inc.), while SKBr3
cells were cultured under the same conditions in 5 mL
MEM/EBSS plus 10% FBS and 1% Pen-Strep. Harvesting
of cells was performed at approximately 80–90% con-
fluency after 5–10 min trypsinization.
Healthy donor blood samples were processed within
24 h from withdrawal, and spiking of cells occurred in
conjunction with subsequent CellSearch analyses. Two
different spiking methods were used. First, dilution of cells
resulted in approximately 2000 cells per 7.5 ml blood, and
using the CTC-DropMount technique (described below),
approximately 200 cells were applied to 10 individual
slides, which were later used in the optimization of stain-
ing procedures. Second, to ascertain the recovery rate of
the method, a specific number of cells were harvested in-
dividually with a 10 μL pipette under a bright-field micro-
scope equipped with a standard achromatic × 10/0.25
objective. In detail, a fraction of the cell culture was trans-
ferred to a Petri dish containing cell culture medium.
While observing the cell culture suspension through the
eyepieces of the microscope, suitable individual cells were
selected and carefully extracted using a 10 μL pipette be-
fore transfer to a healthy donor blood sample. Since the
process is continuously monitored by microscopy, one can
confirm that the cell has been properly extracted. Refer-
ence values of 5, 15, and 50 cells were selected. Independ-
ently collected duplicates of each of the three respective
cell quantities were added to 7.5 mL of healthy donor
blood samples and processed according to the specified
method. The agreement between the measured results
and the reference values was calculated to define the re-
covery rate.
Fixation of samples using CTC-DropMount
CellSearch Profile (Jansen Diagnostics) analysis was per-
formed according to the manufacturer’s protocol, which
involves enrichment of CTCs with magnetic ferrofluid-
associated anti-EpCAM antibodies but no consecutive
staining. The enriched samples were mounted on slides
using a specific procedure developed in-house, CTC-
DropMount. The solution containing isolated CTCs (ap-
proximately 900 μL) was transferred to an 1.5 mL
Eppendorf tube and placed in a magnetic tray. After
10 min incubation, the non-adherent solvent was ex-
tracted. The cells were resuspended in 10 μL 1 × PBS,
mounted on superfrost slides (ThermoScientific,
Germany) and incubated at 37°C for 30 min. Fixation
was accomplished by immersing slides in pure methanol
for 5 min. The samples were stored at −20°C.
The CTC-DropMount method was also used for
enriched cells after standard CellSearch epithelial cellanalysis (i.e. all cells were semi-automatically stained
with CK-phycoerythrin (PE), CD45-allophycocyanin
(APC) and DAPI in a procedure described previously
(3)). In this case, the solution containing enriched CTCs
was extracted from the CellSearch cartridge after
complete analyses, and the cartridge was carefully rinsed
with 1 × PBS buffer to ensure maximum extraction be-
fore transfer to a 1.5 mL Eppendorf tube in a magnetic
tray. An overview of the CTC-DropMount method is
provided in Figure 1.
Immunostaining protocol for ERα and HER2
Following cell permeabilization using Dako Target Retrieval
solution containing Tris/EDTA buffer solution pH 9.0 and
detergent (S2368, Dako Denmark A/S, Glostrup, Denmark),
slides were stained according to the optimized protocols
detailed in Tables 1 and 2, respectively. Briefly, to define
CTCs against the backdrop of remaining leukocytes, a
CD45-specific AlexaFluor647-labeled mouse monoclonal
antibody (F10894, AbD Serotec, Oxford, UK) was assessed
at dilutions of 1:1, 1:5 and 1:10 [32]. The primary antibody
used against ERα was a rabbit monoclonal antibody
(RM-9101-S1, Thermo Scientific, Fremont, CA, USA),
diluted 1:50 [33]. Secondary detection was accom-
plished with AlexaFluor488-labeled goat anti-rabbit
antibody (A-11034, Life Technologies, Carlsbad, CA,
USA) at dilutions of 1:200, 1:300, 1:400, and 1:500. For
detection of cytokeratin, slides were incubated with
CellSearch Staining Reagent containing a PE-labeled
mouse monoclonal antibody specific to CK 8, 18 and
19, at a concentration of 0.0006% (Janssen Diagnostics).
Antibody dilutions were made with DAKO Antibody
Diluent containing 1% FBS in PBS and 0.1% detergent
(S2022, Dako). Slides were finally mounted with cover-
slips and counterstained with an antifade reagent contain-
ing the nucleic acid dye, DAPI, (S36942, Life Technologies),
thus enhancing resistance to photobleaching.
The level of HER2-expression was investigated using a
primary monoclonal rabbit antibody specific for the hu-
man HER2 oncoprotein (1:250; EP1045Y, Abcam plc,
Cambridge, UK), along with a polyclonal porcine anti-
rabbit secondary antibody conjugated with alkaline
phosphatase (ALP) (1:50; D0306, Dako). Detection was
accomplished based on the ALP-Fast Red reaction, using
the substrate and chromogen in Liquid Permanent Red
(LPR) (K0640, Dako [34]). Incubation times assessed for
the ALP-Fast Red reaction were 5, 10 and, 15 min. LPR
was evaluated by both fluorescence and bright-field
microscopy.
Immunofluorescence and bright-field analyses were
performed with an Olympus BX63 microscope equipped
with a dual color/monochrome digital DP80 camera
(Olympus Optical CO., Hamburg, Germany). Single pass
filters for DAPI, GFP/Alexa488, PE/TxRed and APC/
Figure 1 Overview of the method. Enriched CTCs were collected after CellSearch analysis using the Profile or Epithelial cell kit. The solution containing
CTCs and leukocytes was placed in a magnetic tray. Following incubation, the non-adherent solvent was removed and the ferrofluid-attached cells
were re-suspended in a smaller volume of PBS, thus permitting further enrichment. This solution was dropped and fixed on a glass slide before
subsequent staining according to protocols 1 or 2. Visualization is possible with a fluorescence or bright-field microscope, depending on the staining
method applied. (Drawing of magnetic stand reprinted with permission from IFI CLAIMS Patent Services.)
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few cases, an Olympus BX51 microscope (Olympus
Optical CO) and a Zeiss Axio Observer Z1 microscope
(Carl Zeiss Microscopy, LLC., NY, USA) outfitted with
single pass filters for each individual fluorochrome were
used for examination.
In vivo validation
Patient blood samples were investigated for clinical
validation of the technique. All patients had
metastatic breast cancer and had been included in
the ongoing CTC-MBC trial (Clinical Trial Id.
NCT01322893) at Lund University, Sweden. In total,Table 1 Optimized staining protocol for ERα, CK, and CD45 e
Step Reagent
1. Cell fixation Methanol
2. Cell permeabilization Dako Envision Target Retrieval solution™ (50x) (T
buffer solution, pH 9.0, and detergent)
3. AB serum Dako AB diluent™ (1% FBS in PBS, 0.1% detergen
41. ERα labelling Rabbit monoclonal AB specific to ERα
51. CD45 staining Alexa Fluor 647 labeled mouse monoclonal AB s
CD45
62. ERα staining Alexa Fluor 488 labeled goat anti-rabbit seconda
72. Cytokeratin 8, 18,
and 19 staining




Slowfade® Gold antifade with nuclear dye, DAPI
Washing with iced PBS 10.0%, v/v, 3 × 3 min between each step.
Abbreviations: AB - antibody, DAPI - 4′,6-diamidino-2-phenylindole dihydrochloride,
PBS - phosphate buffered saline, RT - room temperature, Tris - 2-Amino-2-hydroxym
1 Step 4 and 5 can be performed simultaneously.
2 Step 6 and 7 can be performed simultaneously.nine clinical samples of 7.5 mL whole blood from
nine individual patients were assessed by CellSearch
profile analysis. CTC-DropMount and subsequent
staining according to the staining protocols detailed
in Tables 1 and 2 were performed prior to evaluation
by fluorescence and bright-field microscopy. All pa-
tient sample analyses were processed in conjunction
with positive and negative controls, decreasing the
risk of methodological errors, as well as confirming
successful staining reactions. Ethical permission for
the CTC-MBC study was obtained from Lund University
Ethical Board (EPN 2010/135) and all patients gave writ-


















pecific to 1:5 60 min
at 37°C
AbD Serotec, UK, #B173123










EDTA - Ethylenediaminetetraacetic acid, ERα - estrogen receptorα,
ethyl-propane-1,3-diol.
Table 2 Optimized staining protocol for HER2 expression
Step Reagent Concentration Interval Manufacturer/Batch
1. Cell fixation Methanol 1:1 5 min
at RT
Merck KGaA, Germany, #I659409
2. Cell
permeabilization
Dako Envision Target Retrieval solution™ (50×) (Tris/EDTA
buffer solution, pH 9.0, and detergent)
1:50 20 min
at 37°C
Dako Denmark, A/S, #20000821
3. AB serum Dako AB diluent™ (1% FBS in PBS, 0.1% detergent) 1:1 20 min
at RT
Dako Denmark, A/S, #00091216
4. HER2 labelling Rabbit monoclonal AB specific to HER2 1:250 20 min
at RT
Abcam plc, United Kingdom,
#GR122507-5
5. ALP conjugation ALP-conjugated porcine polyclonal anti-rabbit AB 1:50 30 min
at RT
Dako Denmark, A/S, #20008362




Dako Denmark, A/S, #10082175
7. Nuclear
counterstaining
Slowfade® Gold antifade with nuclear dye, DAPI Life Technologies, United States,
#1500156
Washing with iced PBS 10.0% (v/v), 3 × 3 min between each step except after LPR when the slides are only quickly rinsed in with PBS before
nuclear counterstaining.
Abbreviations: AB, antibody; ALP, Alkaline phosphatase; DAPI, 4′,6-diamidino-2-phenylindole dihydrochloride; EDTA, Ethylenediaminetetraacetic acid; LPR, liquid
permanent red; PBS, phosphate buffered saline; RT, room temperature; Tris, 2-Amino-2-hydroxymethyl-propane-1,3-diol.
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CTC-DropMount
An overview of the CTC-DropMount technique is
shown in Figure 1. Using CellSearch Profile analysis
from whole blood, the recovery rate was found to be
87% on average (80% for 5 cells, 97% for 15 cells and
84% for 50 cells).
Immunofluorescence
Using the AlexaFluor647-labeled monoclonal CD45-
antibody, it was possible to separate leukocytes from
CTCs under standard fluorescence microscopy. This re-
sult provides an important prerequisite for further stain-
ing and demonstrated sufficient selectivity of the
method (see Figure 2). Optimal distinction between
CTCs and leukocytes was achieved when combining the
two filters for CK-PE and CD45-AlexaFluor647.
Criteria for ERα-positivity defined staining of the nu-
clear region. The process was considered satisfactory
when cells in the ERα+ cell line (MCF7) consistently
stained positive for ERα with low background and
marked nuclear intensity, while slides with ERα− cellsFigure 2 CD45 staining. Secondary staining of cell line cells spiked into he
blue), cytokeratins 8, 18, and 19 (CK) stained with Phycoerythrin (red), CD45
The two juxtaposed CTCs (CK-positive) stained negative for CD45, while the
and negative for CK, illustrating methodological selectivity.(SKBr3) simultaneously stained negative. Representative
images are displayed in Figure 3.
HER2-staining with LPR proved highly selective (see
Figure 4). The ALP-based reaction suits CTCs particularly
well since endogenous enzymatic activity is negligible in
these samples. Hence, the risk of false positives is insignifi-
cant. LPR permits assessment by both fluorescence and
bright-field microscopy. Bright-field microscopy has the
advantage of being easily accessible in most laboratories
and the staining is impervious to fading. Despite the high
background caused by ferrofluid remnants from Cell-
Search analysis, LPR staining was clearly visible. Also, if
combined with CK-PE staining, bright-field microscopy
was preferable due to the risk of bleed-through between
PE and LPR staining in immunofluorescence analyses.
Staining of the fixed cells was optimized mainly using
cells from CellSearch Profile analyses where no previous
staining and permeabilization had affected the cells.
However, the staining procedure was also tested follow-
ing CellSearch epithelial cell analysis, and although these
cells had been previously stained, the results were con-
sistent with previously unstained cells.althy donor blood, from left to right: DAPI counterstain (fluorescent
stained with AlexaFluor 647 (yellow), and a composite of all channels.
leukocytes (white arrows) simultaneously stained positive for CD45
Figure 3 ERα staining of MCF7 and SKBr3 cells. Selective ERα staining demonstrated in MCF7 (ERα+) and SKBr3 (ERα−) cells. From left to right:
DAPI counterstain (fluorescent blue), cytokeratins 8, 18, and 19 (CK) stained with Phycoerythrin (red), estrogen receptor (ERα) stained with
AlexaFluor 488 (green), and a composite of all channels. MCF7 showed positive nuclear staining in AlexaFluor 488 indicating positive ERα
expression, while SKBr3 was negative.
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nine patient samples after CellSearch Profile analysis,
and examples of positive ERα and HER2 staining can be
found in Figure 5. Table 3 outlines the patients’ charac-
teristics with respect to their primary tumors, metasta-
ses, and CTC phenotypes, as well as the total number of
CTCs detected by CellSearch. The majority of detected
CTCs were negative for both ERα and HER2 expression.
We observed considerable intrapatient heterogeneity in
levels of biomarker expression and cell morphology, ob-
servations that are in concordance with previous re-
search [33]. A visual comparison to corresponding CTCs
in the picture galleries from CellSearch epithelial cell
analyses suggested that the most intensely stained CTCs
were also the most distinctly stained with the CTC-
DropMount method for all investigated markers.
Discussion
In this study, we present a method for secondary
characterization of breast cancer CTCs after CellSearch
analysis. Protocols for the clinically important predictive
markers ERα and HER2 were optimized in breast cancer
cell lines and subsequently verified in samples from pa-
tients with metastatic breast cancer. Fixation of CTCs
was performed with the CTC-DropMount method de-
scribed here, and ERα and HER2 staining protocols
proved selective and consistent in our in vitro model
system.
Secondary phenotypic characterization of fixed CTCs
on standard microscope slides provides the possibility of
concurrent morphological evaluation, assessment of the
total number of cells and an estimation of the fraction of
CTCs with expression of the analyzed biomarker. This
gives unique information on the heterogeneity of marker
expression, which is not available using PCR-basedmolecular methods, for example [28,35,36]. Assessment
of ERα status in CTCs could identify patients eligible for
endocrine treatment that otherwise may be overlooked
(i.e. ERα− primary tumor/ERα+ CTCs). Two of the nine
patients included in the in vivo validation experiments
presented ERα+ CTCs (see Table 3, and representative
images in Figure 5). Both of these samples were drawn
at or just prior to initiation of treatment against meta-
static disease. The phenotype of the primary tumor from
one patient was classified as ERα+, while the second pa-
tient had a confirmed ERα+ metastatic biopsy (Table 3).
Conversely, detection of ERα− CTCs in a patient with an
ERα+ primary tumor might, in part, explain the lack of
treatment response observed in this cohort. A similar
assumption regarding HER2 gene amplification seems
reasonable, since a subset of patients acquire oncogene
amplification during disease progression [30]. The true
number of patients suited for HER2-targeted treatment
may in fact be higher than the number treated at
present. This is currently being investigated in the
ongoing European DETECT III and CIRCE T-DM1
studies, where the CTC HER2-positive phenotype is
used as a treatment predictive marker [31]. In this study,
HER2+ CTCs were identified after 6 months of chemo-
therapy in a metastatic breast cancer patient with a
HER2− primary tumor and a HER2− metastasis biopsy
(see Table 3 and Figure 5).
A few previous studies have used immunological stain-
ing methods for secondary phenotypic characterization.
Swennenhuis et al. fixed CTCs within the cartridge after
complete CellSearch analysis using immunofluorescence
and FISH analysis for successful characterization of
HER2-status [37]. However, the CellTracks II analyzer
had to be modified to improve the resolution and light
collection. Other studies have used the FITC-channel in
Figure 4 HER2-staining of MCF7 and SKBr3. Selective HER2 staining demonstrated in MCF7 (HER2−) and SKBr3 (HER2+) cells. First row: MCF7, from
left to right: DAPI counterstain (fluorescent blue), HER2 stained with Liquid Permanent Red (red), and a composite of all channels. Second row:
SKBr3, in the corresponding channels. Positive membrane staining was visible in SKBr3 cells only. Additionally, assessment of HER2 staining was
also possible using bright-field microscopy, as demonstrated in the lower two rows (third row: MCF7, and fourth row: SKBr3).
Frithiof et al. Journal of Translational Medicine  (2015) 13:126 Page 7 of 10the CellSearch system, where the intensity of HER2
staining is scored as negative (0), very weak (1+), moder-
ate (2+) or very bright (3+) [27,38,39]. The clinical value
of specific cut-off thresholds remains to be determined.
Paoletti et al. recently reported a method utilizing the
CellSearch-integrated FITC-channel for analysis of ERα,
HER2, Ki67, and BCL-2 in individual blood samples with
the intention of predicting resistance to endocrine ther-
apy [40]. By implementing this approach, 7.5 mL of
blood is required for analysis of each respective bio-
marker. Few studies have described methods for second-
ary characterization of ERα and HER2 in CTCs afterFicoll density gradient separation and cytospin prepara-
tions [17,33]. An advantage in circumventing immuno-
logical enrichment before fixation of the cells onto
microscope slides is the exemption from EpCAM-
dependent selection. On the other hand, the number of
cells that have to be screened manually by standard
microscopy is very high, thus hampering the clinical
feasibility and cost effectiveness if introduced into rou-
tine clinical practice.
Fixation of CTCs on microscope slides with the de-
scribed CTC-DropMount method provides the possibil-
ity to use a standard fluorescence microscope for CTC
Figure 5 Immunostaining of metastatic breast cancer patient blood samples. Representative images of positive ERα and HER2 staining in clinical
samples. Row A, from left to right: DAPI counterstain (fluorescent blue), cytokeratins 8, 18, and 19 (CK) stained with Phycoerythrin (red), estrogen
receptor (ERα) stained with AlexaFluor 488 (green), and a composite of all channels. This patient sample (no. 4, see Table 3) was collected prior to
initiation of therapy, illustrating two clustered ERα+ CTCs, adjacent to a solitary leukocyte located in the lower left corner. This patient was
diagnosed with an ERα+ metastasis. Row B, from left to right: DAPI counterstain (fluorescent blue), HER2 stained with Liquid Permanent Red (red).
This patient sample (no. 1, see Table 3) was obtained following 6 months of chemotherapy, illustrating HER2+ CTCs identified by combination of
fluorescence and bright-field microscopy. This patient was diagnosed with a HER2− primary tumor and HER2− metastasis.
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the FDA-cleared CellSearch system. An advantage of the
described method for secondary characterization is the
scope to expand the CTC analysis to other putative pre-
dictive markers as well as to more experimental markers,
for example stem cell markers, epithelial mesenchymal
transition (EMT) markers or markers associated with
metastasis, proliferation or apoptosis, thus increasing
our knowledge of metastasis biology. Selection of single
CTCs or a subset of CTCs is also possible after CTC-
DropMount using laser capture microdissection, for ex-











1 ER+/HER2− ER−/HER2− 48 ER−/HER2+
2 ER+/HER2− n/a 35 ER−/HER2−
3 ER+/HER2− ER+/HER2− 3 n/a‡
4 n/a ER+/HER2− 12 ER+/HER2−
5 ER−/HER2+ n/a 111 ER−/HER2−
6 ER−/HER2+ n/a 311 ER−/HER2−
7 ER+/HER2− ER+/HER2− 107 ER+/HER2−
8 ER+/HER2− ER+/HER2− 0 Negative control
9 ER+/HER2− ER+/HER2− 0 Negative control
*As defined by CellSearch, single samples assessed 0–6 months from initiation
of therapy against metastatic disease.
§Phenotype according to CTC-DropMount. Criteria for biomarker positivity
were ≥1 ER+ CTC, and ≥1 HER2+ CTC.
‡In this patient no CTCs were identified following secondary staining.
Patients 8, and 9 were selected as negative controls. Neither of these patients
had detectable CTCs following secondary staining.open the door to an even more detailed molecular
characterization of CTCs [41].
The informative advantage of heterogeneity in marker
expression using secondary staining methods is also as-
sociated with the need for a prognostic cut-off value for
the fraction or intensity of expression within the CTC
population [17]. Using different cut-offs for marker posi-
tivity has given conflicting results regarding discordance
of marker expression between primary tumors and
CTCs [17,33,42]. Thus, the prognostic significance of
marker heterogeneity in breast cancer CTCs has to be
determined, and reliability on the staining methodology
is of immense importance. Using the CTC-DropMount
technique, we found distinct nuclear staining of ERα in
the MCF7 cell line and used nuclear staining as a criter-
ion for ERα-positivity. However, to effectively determine
the clinical implications, defined criteria, such as the
number of CTCs to be evaluated and the fraction of
ERα- or HER2-positive CTCs, has to be decided in fu-
ture clinical studies.
The cell recovery rate after CTC-DropMount fixation
was 87%, which is at the high end of recovery compared
with studies using different methods for enrichment, fix-
ation and detection [33,43-48]. The 80% recovery rate of
five spiked cell line cells further indicates that this
method could be useful in the clinical setting, where
number of CTCs at the established CellSearch cut-off
value (≥5 CTCs in metastatic breast cancer) is common.Conclusions
In conclusion, our results indicate that by retrieval of a
single blood sample from patients with metastatic breast
cancer it is possible to ascertain the status of important
Frithiof et al. Journal of Translational Medicine  (2015) 13:126 Page 9 of 10predictive biomarkers expressed in breast cancer CTCs.
The discordance of expression between primary tumors
and metastases urgently informs us that new diagnostic
tools are required for optimal treatment selection in
both primary and metastatic breast cancer.
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